Search details
1.
Targeting inflammatory signaling in obsessive compulsive disorder: a promising approach.
Metab Brain Dis
; 39(2): 335-346, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37950815
2.
Targeting inflammation: a potential approach for the treatment of depression.
Metab Brain Dis
; 38(1): 45-59, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36239867
3.
Effects of Current Psychotropic Drugs on Inflammation and Immune System.
Adv Exp Med Biol
; 1411: 407-434, 2023.
Article
in English
| MEDLINE | ID: mdl-36949320
4.
Piperazine analogs of naphthyridine-3-carboxamides and indole-2-carboxamides: novel 5-HT3 receptor antagonists with antidepressant-like activity.
Arch Pharm (Weinheim)
; 348(1): 34-45, 2015 Jan.
Article
in English
| MEDLINE | ID: mdl-25581677
5.
Potential of postbiotics for the treatment of metabolic disorders.
Drug Discov Today
; 29(4): 103921, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38382867
6.
2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: novel 5-HT3 receptor antagonists with anxiolytic-like activity in rodent behavioral models.
Can J Physiol Pharmacol
; 91(10): 848-54, 2013 Oct.
Article
in English
| MEDLINE | ID: mdl-24144056
7.
Anxiolytic-like effect of etazolate, a type 4 phosphodiesterase inhibitor in experimental models of anxiety.
Indian J Exp Biol
; 51(6): 444-9, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23926692
8.
Anxiolytic-like effect of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (60) in experimental mouse models of anxiety.
Indian J Exp Biol
; 51(7): 510-4, 2013 Jul.
Article
in English
| MEDLINE | ID: mdl-23898549
9.
Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist.
Indian J Exp Biol
; 51(6): 435-43, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23926691
10.
Targeting inflammatory pathways for treatment of the major depressive disorder.
Drug Discov Today
; 28(9): 103697, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37422168
11.
Small-molecule oligonucleotides as smart modality for antiviral therapy: a medicinal chemistry perspective.
Future Med Chem
; 15(12): 1091-1110, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37584172
12.
Role of Brain-Gut-Microbiota Axis in Depression: Emerging Therapeutic Avenues.
CNS Neurol Disord Drug Targets
; 22(2): 276-288, 2023.
Article
in English
| MEDLINE | ID: mdl-35352640
13.
Aducanumab in Alzheimer's disease: A critical update.
Curr Med Chem
; 2023 Jul 27.
Article
in English
| MEDLINE | ID: mdl-37497712
14.
Ligand-based design, synthesis, and pharmacological evaluation of 3-Methoxyquinoxalin-2-carboxamides as structurally novel serotonin type-3 receptor antagonists.
Arch Pharm (Weinheim)
; 345(9): 687-94, 2012 Sep.
Article
in English
| MEDLINE | ID: mdl-22674774
15.
Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models.
Indian J Exp Biol
; 50(9): 625-32, 2012 Sep.
Article
in English
| MEDLINE | ID: mdl-23140020
16.
Biocomposite-based nanostructured delivery systems for the treatment and control of inflammatory lung diseases.
Nanomedicine (Lond)
; 17(12): 845-863, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35477308
17.
Ameliorative Potential of Rosuvastatin on Doxorubicin-induced Cardiotoxicity by Modulating Oxidative Damage in Rats
Turk J Pharm Sci
; 19(1): 28-34, 2022 02 28.
Article
in English
| MEDLINE | ID: mdl-35227038
18.
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases.
Drug Discov Today
; 27(5): 1431-1440, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35017085
19.
Investigation of Cochlospermum religiosum leaves for antidepressant and anxiolytic activities and its synergistic effect with imipramine and fluoxetine.
Environ Sci Pollut Res Int
; 29(18): 27172-27181, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-34981394
20.
Impact of ecDNA: A mechanism that directs tumorigenesis in cancer drug Resistance-A review.
Chem Biol Interact
; 363: 110000, 2022 Aug 25.
Article
in English
| MEDLINE | ID: mdl-35671828